Novo Nordisk A/S Class B Overview
Novo Nordisk A/S Class B (NONOF) has a ROE of 60.03%, above the Healthcare sector average of 29.39%.
Get informed when a big investor buys or sells
+ Follow60.03%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, NONOF shows a ROE of 60.03%. That is above the Healthcare sector average of 29.39%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 29.39%. Novo Nordisk A/S Class B is at 60.03%, which is higher that average. That is roughly 104.2% above the sector mean. Use the comparison chart on this page to see how NONOF stacks up against individual peers as well.
Check the historical chart to see whether NONOF's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Novo Nordisk A/S Class B with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Novo Nordisk A/S Class B's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 60.03%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 29.39%, while NONOF is at 60.03%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
